BACKGROUND: Glucagon-like peptide-1 receptor agonists provide effective @entity4854 management in @entity1 with @entity164 2 @entity6 . In a randomized head-to-head trial, liraglutide 1.8 mg once daily (OD) led to greater reductions in glycated hemoglobin (HbA1c ) level than exenatide 10   g twice daily (BID). There are no direct comparisons of liraglutide 1.2 mg OD and exenatide BID, therefore an indirect comparison and meta-analysis were undertaken. METHODS: A systematic literature search was performed for randomized, controlled trials of liraglutide 1.2 mg OD or exenatide BID with HbA1c as an outcome and n>= 25 subjects. Key data were extracted and analyzed. A random effects model was used to incorporate heterogeneity between studies. RESULTS: Three liraglutide 1.2 mg OD (n=1060) and ten exenatide BID (n=2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm. Baseline characteristics: mean age ~55 years; disease duration ~7 years; @entity4051 c ~8%; BMI ~32 kg/m(2) . Compared with exenatide BID, liraglutide 1.2 mg was associated with significantly greater reductions from baseline in HbA1c (-0.29%; 95%CI -0.53, -0.05) and fasting plasma @entity413 (-0.92 mmol/L; 95%CI -1.43, -0.41) with shorter duration of @entity390 (3 vs. 14 days; p=0.002) and fewer withdrawals (odds ratio, 0.34; 95%CI 0.22, 0.52). The incidence of adverse events (including @entity390 ) and withdrawals due to adverse events were similar between treatments. CONCLUSIONS: Liraglutide 1.2 mg provided a statistically significantly greater reduction in HbA1c than exenatide 10   g BID. The significantly shorter duration of @entity390 with liraglutide vs. exenatide may be appreciated by @entity1 . This article is protected by copyright. All rights reserved.

Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10   g) in the treatment of @entity164 2 XXXX @entity1 : An indirect treatment comparison meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
